Purpose As one of the most effective analgesics, opioids are essential for patients with
cancer-related pain, even in the context of the opioid abuse crisis. The current meta-analysis …

Background: Immune checkpoint inhibitors (ICIs) represent one of the most effective
treatments for patients with cancer. As their activity relies on host immune system reactivity …

Cancer is a leading cause of morbidity and mortality worldwide, with pain experienced by
most patients undergoing cancer treatment. Opioids are the recommended treatment for …

Background Drug–drug interactions (DDIs) pose new challenges beyond traditional
pharmacodynamics in the context of optimizing the treatment options with immune …

Abstract Objective Immune checkpoint inhibitors (ICIs) have effectively improved the clinical
outcome of advanced non-small cell lung cancer (NSCLC). Opioids are commonly used for …

Purpose Medications regulating immune homeostasis and gut microbiota could affect the
efficacy of immune checkpoint inhibitors (ICIs). This study aimed to investigate the impact of …

Objective A retrospective clinical study was conducted to compare the prognosis between
the opioid analgesic (OA) treated and OA-untreated groups and to evaluate the effect of …

Background Opioids represent the pharmacological backbone of cancer-related pain
treatment. However, preclinical studies suggest that opioids can cause immunosuppression …

Background Immune checkpoint inhibitors (CPIs) have been shown to improve overall
survival and disease-free survival in patients with non-small cell lung cancer (NSCLC), but …

What is known and objective: Clinical cases of attenuation of opioid analgesic effect by
administration of immune checkpoint inhibitors has not been reported. We present a case of …